Merck, Endocyte Report Vintafolide-PLD Generaly Well Tolerated, Showed Median PFS of Five Months
October 14, 2013 at 17:07 PM EDT
Merck, known as MSD outside the United States and Canada, (NYSE: MRK ) and Endocyte, Inc. (NASDAQ: ECYT ) today announced the online publication of results from the randomized Phase II PRECEDENT trial for vintafolide (MK-8109/EC145), an investigational folate small molecule drug conjugate (SMDC), in the Journal of Clinical Oncology (JCO), the
